{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:02:51Z","timestamp":1789556571334,"version":"build-2803163510"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD24 is widely recognized as a developmental marker of early B-cell differentiation and is highly expressed in precursor B-cell acute lymphoblastic leukemia (B-ALL). However, CD24 expression alone does not fully explain its biological activity, suggesting that post-translational regulation, particularly glycosylation, may determine its immune-regulatory functions. Although the CD24\u2013Siglec-10 axis has emerged as an important innate immune checkpoint, how developmental CD24 expression is functionally adapted during leukemogenesis remains poorly understood. Here, we propose a framework in which CD24 functions as a glyco-immune checkpoint whose activity is determined by functional glycoforms rather than protein abundance alone. We discuss how physiological CD24 expression during B-cell ontogeny may contribute to developmental immune tolerance and propose that this program can be retained, hijacked, or remodeled during leukemogenesis through altered glycosylation patterns. Such glyco-adaptation may enhance CD24\u2013Siglec-10-mediated suppression of macrophage surveillance, allowing leukemia cells to evade innate immune recognition and persist as minimal residual disease. We further propose that glycosylation-dependent immune adaptation represents an additional layer of leukemia evolution that complements genetic and epigenetic alterations. This perspective integrates developmental biology, glycobiology, innate immunity, and leukemia biology to establish the emerging field of leukemia glycoimmunology. Finally, we discuss the translational implications of CD24 glycobiology, including glycoform-based biomarkers, functional immune profiling, glycosylation-directed therapeutic strategies, and modulation of glycan remodeling pathways. Understanding how glycosylation shapes CD24 function may provide new opportunities for precision immunotherapy in B-ALL.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1952918","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:12:31Z","timestamp":1789553551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glycosylation converts CD24 from a developmental marker into a glyco-immune checkpoint in B-cell acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuheng","family":"Yan","sequence":"first","affiliation":[{"name":"Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University","place":["Dalian, China"]},{"name":"Department of Translational Genomics, Keck School of Medicine of the University of Southern California","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81692-x","article-title":"Stem cells: units of development, units of regeneration, and units in evolution","volume":"100","author":"Weissman","year":"2000","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3801","article-title":"The early history of B cells","volume":"15","author":"Cooper","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.633825","article-title":"Spatial organization of chromatin: Transcriptional control of adaptive immune cell development","volume":"12","author":"Pongubala","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2009.119","article-title":"CD24: from A to Z","volume":"7","author":"Fang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2005.08.026","article-title":"Expression of CD24 on CD19- CD79a+ early B-cell progenitors in human bone marrow","volume":"236","author":"Israel","year":"2005","journal-title":"Cell Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S366625","article-title":"CD24 as a potential therapeutic target in patients with B-cell leukemia and lymphoma: Current insights","volume":"15","author":"Christian","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33249","article-title":"Novel insights into the function of CD24: A driving force in cancer","volume":"148","author":"Altevogt","year":"2021","journal-title":"Int J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2010.70","article-title":"Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis","volume":"90","author":"Kristiansen","year":"2010","journal-title":"Lab Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071111","article-title":"The flow cytometric evaluation of B- and T-lymphoblastic leukemia\/lymphoma","volume":"17","author":"Dorfman","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2016.05.038","article-title":"Analysis of the structure, evolution, and expression of CD24, an important regulator of cell fate","volume":"590","author":"Ayre","year":"2016","journal-title":"Gene"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cyto.b.22104","article-title":"Circulating CD22+\/CD19-\/CD24- progenitors and CD22+\/CD19+\/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia","volume":"104","author":"Zhou","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080724","article-title":"Feasibly of CD24\/CD11b as a screening test for hematological Malignancies","volume":"11","author":"Shapira","year":"2021","journal-title":"J Pers Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094881","article-title":"The evolving landscape of flowcytometric minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"Verbeek","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015072","article-title":"Emerging immune checkpoint molecules on cancer cells: CD24 and CD200","volume":"24","author":"Moon","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70271","article-title":"CD24 in melanoma: Biomarker, innate immune checkpoint and emerging therapeutic target","volume":"35","author":"Lasalle","year":"2026","journal-title":"Exp Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1174789","article-title":"CD24-Siglec interactions in inflammatory diseases","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1798585","article-title":"CD24 as an innate immune checkpoint in solid tumors: Biology, biomarker stratification, and therapeutic translation","volume":"17","author":"Zhou","year":"2026","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367959","article-title":"Checkpoint CD24 function on tumor and immunotherapy","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-2616","article-title":"Radiation-enhanced CD24 membrane trafficking via GPI anchoring mediates antitumor immune evasion","volume":"86","author":"Kong","year":"2026","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071446","article-title":"Glycosylation and its role in immune checkpoint proteins: From molecular mechanisms to clinical implications","volume":"12","author":"Liu","year":"2024","journal-title":"Biomedicines"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101925","article-title":"Roles for Siglec-glycan interactions in regulating immune cells","volume":"77","author":"Lin","year":"2025","journal-title":"Semin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","article-title":"Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses","volume":"77","author":"Laubli","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01324","article-title":"Molecular mechanism of tumor cell immune escape mediated by CD24\/Siglec-10","volume":"11","author":"Yin","year":"2020","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-008-8043-z","article-title":"Transcriptional regulation of early B cell development","volume":"42","author":"Northrup","year":"2008","journal-title":"Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2016.00146","article-title":"CD24: A rheostat that modulates cell surface receptor signaling of diverse receptors","volume":"4","author":"Ayre","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02423","article-title":"The role of the pre-B cell receptor in B cell development, repertoire selection, and tolerance","volume":"9","author":"Winkler","year":"2018","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78083","article-title":"Checkpoints that control B cell development","volume":"125","author":"Melchers","year":"2015","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwu068","article-title":"Siglec-G\/10 in self-nonself discrimination of innate and adaptive immunity","volume":"24","author":"Chen","year":"2014","journal-title":"Glycobiology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1146\/annurev-biochem-060614-034420","article-title":"Understanding the chemistry and biology of glycosylation with glycan synthesis","volume":"85","author":"Krasnova","year":"2016","journal-title":"Annu Rev Biochem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01074-1","article-title":"Immune regulatory networks coordinated by glycans and glycan-binding proteins in autoimmunity and infection","volume":"20","author":"Pinho","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451318","article-title":"Tumor glycosylation: A main player in the modulation of immune responses","volume":"55","author":"Rodriguez","year":"2025","journal-title":"Eur J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.07.005","article-title":"CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0264","article-title":"Glycans as immune checkpoints: Removal of branched N-glycans enhances immune recognition preventing cancer progression","volume":"8","author":"Silva","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158165","article-title":"Glycosylation modulates plasma membrane trafficking of CD24 in breast cancer cells","volume":"22","author":"Chantziou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01419-0","article-title":"STT3-mediated aberrant N-glycosylation of CD24 inhibits paclitaxel sensitivity in triple-negative breast cancer","volume":"46","author":"Wang","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12081235","article-title":"CD24: A novel target for cancer immunotherapy","volume":"12","author":"Panagiotou","year":"2022","journal-title":"J Pers Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12610","article-title":"Altered glycosylation in cancer: Molecular functions and therapeutic potential","volume":"44","author":"Xu","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadva.2024.100125","article-title":"Emerging technologies for single-cell glycomics","volume":"6","author":"Keisham","year":"2024","journal-title":"BBA Adv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadva.2025.100146","article-title":"Toward spatial glycomics and glycoproteomics: Innovations and applications","volume":"7","author":"Boottanun","year":"2025","journal-title":"BBA Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251810231","article-title":"Lectin-based approaches to analyze the role of glycans and their clinical application in disease","volume":"25","author":"Ideo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2009.044","article-title":"O-glycosylation pattern of CD24 from mouse brain","volume":"390","author":"Bleckmann","year":"2009","journal-title":"Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1021\/pr800729r","article-title":"Glycomic analysis of N-linked carbohydrate epitopes from CD24 of mouse brain","volume":"8","author":"Bleckmann","year":"2009","journal-title":"J Proteome Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2026.117620","article-title":"Deciphering super-heterogeneous glycosylated biotherapeutics by combining hydrophilic interaction chromatography-based separation and scan-by-scan deconvolution strategy","volume":"281","author":"Zhang","year":"2026","journal-title":"J Pharm BioMed Anal"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cells14010009","article-title":"ST8SIA6 sialylates CD24 to enhance its membrane localization in BRCA","volume":"14","author":"He","year":"2024","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2026.101139","article-title":"CRISPR activation screens map the genomic landscape of cancer glycome remodeling","volume":"6","author":"Daly","year":"2026","journal-title":"Cell Genom"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2026.111249","article-title":"Writers and readers of sialylation in immunoregulation in cancer","volume":"302","author":"Decloquement","year":"2026","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2026.01.018","article-title":"Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10","volume":"34","author":"Medina","year":"2026","journal-title":"Structure"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02820","article-title":"B cell siglecs-news on signaling and its interplay with ligand binding","volume":"9","author":"Meyer","year":"2018","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71086-8","article-title":"An atlas of human siglecs integrates expression, affinity, and cis\/trans sialoglycan recognition profiles","volume":"17","author":"Leviatan Ben-Arye","year":"2026","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302875","article-title":"The ligand-binding domain of Siglec-G is crucial for its selective inhibitory function on B1 cells","volume":"192","author":"Hutzler","year":"2014","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256420","article-title":"The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia","volume":"24","author":"Roder","year":"2023","journal-title":"EMBO Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-024-01532-x","article-title":"Decoding the glycoproteome: a new frontier for biomarker discovery in cancer","volume":"17","author":"He","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting CD24\/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1046\/j.0014-2956.2001.02543.x","article-title":"A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33","volume":"268","author":"Whitney","year":"2001","journal-title":"Eur J Biochem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081847","article-title":"Minimal residual disease in acute lymphoblastic leukemia: current practice and future directions","volume":"13","author":"Contreras Yametti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/asheducation-2017.1.13","article-title":"Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation","volume":"2017","author":"Bruggemann","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18091331","article-title":"Measurable residual disease in adult acute B-lymphoblastic leukemia: methods, guidelines, and emerging actionability at ultra-low-level","volume":"18","author":"Yaseen","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s43556-025-00352-w","article-title":"Drug resistance in cancer: molecular mechanisms and emerging treatment strategies","volume":"6","author":"Li","year":"2025","journal-title":"Mol BioMed"},{"key":"B63","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/0008-5472.BCD-19-0041","article-title":"Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia","volume":"1","author":"Waanders","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094426","article-title":"The bone marrow niche in B-cell acute lymphoblastic leukemia: the role of microenvironment from pre-leukemia to overt leukemia","volume":"22","author":"Dander","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06237-w","article-title":"Tumor microenvironment as a novel therapeutic target for lymphoid leukemias","volume":"104","author":"Mousavi","year":"2025","journal-title":"Ann Hematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112738","article-title":"Cancer immunoediting by the innate immune system in the absence of adaptive immunity","volume":"209","author":"O'Sullivan","year":"2012","journal-title":"J Exp Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1766555","article-title":"Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression","volume":"17","author":"Lau","year":"2026","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300366120","article-title":"Targeted glycan degradation potentiates cellular immunotherapy for solid tumors","volume":"120","author":"Wu","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.07.006","article-title":"Targeting glycans for CAR therapy: the advent of sweet CARs","volume":"30","author":"Raglow","year":"2022","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17183027","article-title":"CAR-T cell therapies in B-cell acute lymphoblastic leukemia: emerging data and open issues","volume":"17","author":"Alati","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2349796","article-title":"Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis","volume":"56","author":"Willyanto","year":"2024","journal-title":"Ann Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181596","article-title":"Overcoming antigen escape and T-cell exhaustion in CAR-T therapy for leukemia","volume":"13","author":"Bartoszewska","year":"2024","journal-title":"Cells"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4410","article-title":"Clonal evolution in leukemia","volume":"23","author":"Ferrando","year":"2017","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006996","article-title":"Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia","volume":"137","author":"Alberti-Servera","year":"2021","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.13142","article-title":"Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia","volume":"168","author":"Sutton","year":"2015","journal-title":"Br J Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1743920","article-title":"The tumor microenvironment in leukemia: molecular pathways of immune evasion","volume":"17","author":"Zhu","year":"2026","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1952918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:12:32Z","timestamp":1789553552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1952918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2026.1952918"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1952918","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1952918"}}